40 MILLION PEOPLE LIVE WITH KIDNEY DISEASES.

700,000 INDIVIDUALS HAVE KIDNEY FAILURE.

THERE IS NO CURE.

KIDNEY X
INNOVATION ACCELERATOR
KidneyX is a public-private partnership to

Reward and incentivize breakthrough innovations in kidney care by funding new ideas through a series of competitive prizes

Clear a path to commercialization for disruptive therapies and technologies by providing better coordination among HHS, NIH, FDA, and CMS

Create a sense of urgency to bring breakthrough therapies to patients, including fostering multidisciplinary collaboration and engaging the investment community

“Dialysis today doesn’t look much different than it did 60 years ago. More innovation is needed, because patients deserve better.”

— Eric D. Hargan, Deputy Secretary of the Department of Health and Human Services
Why KidneyX is Needed

- Medicare annually spends $35 billion treating kidney failure and $114 billion managing kidney diseases.
- Kidney failure is still managed with dialysis, a therapy invented 50 years ago, and there are no cures.
- Lack of private investment and venture capital, misaligned government incentives, and a complex regulatory process inhibit innovative ideas from becoming therapies available to patients.

Why KidneyX is the Solution

- Incentivizes the accelerated development and commercialization of disruptive technologies.
- Provides merit-based, non-dilutive funding to promising innovators selected through a competitive process for kidney patients to address unmet patient needs.
- Bridges the gap between research and market-ready products.

<table>
<thead>
<tr>
<th>PUBLIC</th>
<th>PRIVATE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$25M</strong>&lt;br&gt;FY20 congressional appropriation support</td>
<td><strong>$25M</strong>&lt;br&gt;committed by ASN</td>
</tr>
<tr>
<td><strong>$125M</strong>&lt;br&gt;congressional funding over 5 years</td>
<td><strong>$100M</strong>&lt;br&gt;in fundraising over 5 years</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARTNERSHIP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$250M total</strong>&lt;br&gt;driving kidney innovation over 5 years</td>
</tr>
</tbody>
</table>
KidneyX Focus Areas + Potential Products

**REDESIGN DIALYSIS: October 2018 - Q2 2020**
Wearable or implantable dialyzers, bio-artificial kidneys, xenotransplant technology, etc.

**MEDICATIONS**
Drugs specifically designed to treat and slow progression of kidney diseases, as well as encompass the needs of kidney transplant patients

**DEVICES**
Devices that support the management and treatment of kidney diseases that are not dialyzers (such as vascular access technologies, etc.)

**DIAGNOSTICS**
Point-of-care or at home testing kits, real time kidney monitoring, etc.

**PATIENT-CENTERED TOOLS**
Tools designed to identify and track disease, applications to empower patients to manage kidney diseases (e.g., apps)

For more information, please contact Rachel Meyer at rmeyer@asn-online.org or visit www.KidneyX.org.